Premium
Disopyramide pharmacokinetics during recovery from myocardial infarction.
Author(s) -
Bryson SM,
Cairns CJ,
Whiting B
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb01395.x
Subject(s) - disopyramide , pharmacokinetics , bioavailability , volume of distribution , medicine , myocardial infarction , pharmacology , half life , oral administration , renal function , anesthesia
1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half‐lives which undermine accepted dosage recommendations. 2 Disopyramide pharmacokinetics were investigated after intravenous and oral administration to nine such patients. 3 Mean elimination half‐life (6.82 h) and bioavailability (79.8%) were consistent with findings from a previous study in young healthy volunteers. 4 Volume of distribution was reduced by 25%: the mean +/‐ s.d. value was 0.61 +/‐ 0.17 l/kg. Total body clearance was significantly reduced: the mean +/‐ s.d. value was 1.02 +/‐ 0.16 ml min‐1 kg‐1. 5 These figures indicate that, in this patient group, if renal function is not significantly impaired, a standard loading dose of 2 mg/kg should be followed by the appropriate maintenance dose administered three or four times daily.